Fig. 3

Intratumoral administration of TLR9 agonist reprograms the tumor microenvironment, with increased infiltration and activation of adaptive CD8 T cells. A. Multiparametric flow cytometry analysis of tumor infiltrating CD8 T cells in both treated and untreated lesions from SD101- or PBS-treated mice. Data from single mice are shown (4–5 mice per group; a representative experiment is shown). Mann–Whitney test was used for statistical analysis. B. Representative immunohistochemistry staining of CD8 on tumor lesions. C. Immunofluorescence analysis for CD8 (green) and Ki67 (pink) on tumor lesions (DAPI:blue). White arrows indicated double stained cells. Upper panel:PBS-treated control lesion; middle panel: SD101-treated lesion; lower panel: SD101-untreated lesion. D. Multiparametric flow cytometry analysis of tumor infiltrating CD4 T cells in both treated and untreated lesions from SD101- or PBS-treated mice. Data from single mice are shown (4–5 mice per group; a representative experiment is shown). Mann–Whitney test was used for statistical analysis